These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 23936821

  • 1. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.
    Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, De Nicola S, Cheroni C, Grassi E, Colombo M.
    Biomed Res Int; 2013; 2013():580796. PubMed ID: 23936821
    [Abstract] [Full Text] [Related]

  • 2. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS.
    PLoS One; 2011 Mar 30; 6(3):e18322. PubMed ID: 21479134
    [Abstract] [Full Text] [Related]

  • 3. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.
    Antivir Ther; 2012 Mar 30; 17(6):1059-67. PubMed ID: 22898703
    [Abstract] [Full Text] [Related]

  • 4. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM.
    AIDS; 2011 May 15; 25(8):1025-33. PubMed ID: 21505315
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA.
    J Infect; 2013 Jul 15; 67(1):59-64. PubMed ID: 23542783
    [Abstract] [Full Text] [Related]

  • 8. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H, Guo LL, He LL, Chen Y, Liu K, Lei BJ, Lei XZ.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov 15; 43(6):855-9. PubMed ID: 23387213
    [Abstract] [Full Text] [Related]

  • 9. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
    Mandorfer M, Neukam K, Reiberger T, Payer BA, Rivero A, Puoti M, Boesecke C, Baumgarten A, Grzeszczuk A, Zangerle R, Meyer-Olson D, Rockstroh JK, Trauner M, Pineda JA, Peck-Radosavljevic M.
    AIDS; 2013 Nov 13; 27(17):2707-14. PubMed ID: 23835502
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.
    Acta Biochim Pol; 2012 Nov 13; 59(3):333-7. PubMed ID: 22924160
    [Abstract] [Full Text] [Related]

  • 14. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
    Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K.
    J Viral Hepat; 2011 Jul 13; 18(7):e325-31. PubMed ID: 21692944
    [Abstract] [Full Text] [Related]

  • 15. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.
    Int J Infect Dis; 2015 Jan 13; 30():91-7. PubMed ID: 25462177
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.
    J Viral Hepat; 2014 Mar 13; 21(3):178-88. PubMed ID: 24438679
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
    Corchado S, López-Cortés LF, Rivero-Juárez A, Torres-Cornejo A, Rivero A, Márquez-Coello M, Girón-González JA.
    PLoS One; 2014 Mar 13; 9(7):e101760. PubMed ID: 25013899
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.